Quick Answer
CERO THERAPEUTICS HOLDINGS, INC. reported Operating Income of -$15.30 million for fiscal year 2024.
CERO THERAPEUTICS HOLDINGS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$15.30M | -1605.5% |
| 2024 | -$897.1K | +88.3% |
| 2023 | -$7.68M | -164.2% |
| 2022 | -$2.91M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.36M | +0.9% | +7.6% |
| June 30, 2025 | -$4.72M | +8.2% | +4.6% |
| March 31, 2025 | -$4.95M | -35.4% | -12.5% |
| September 30, 2024 | -$4.40M | -924.3% | +14.5% |
| June 30, 2024 | -$5.15M | -113.3% | -40.9% |
| March 31, 2024 | -$3.65M | -49.9% | -307.4% |
| January 31, 2024 | -$897.1K | — | -108.7% |
| September 30, 2023 | -$429.8K | +48.6% | +82.2% |
- CERO THERAPEUTICS HOLDINGS, INC. showed a decrease of -1605.5% in Operating Income compared to the prior fiscal year.
- Over the 2022–2024 period, CERO THERAPEUTICS HOLDINGS, INC.’s operating income has declined by 426.6% (from -$2.91 million to -$15.30 million).
- The most recent figure is from CERO THERAPEUTICS HOLDINGS, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: